TY - JOUR
T1 - Bendamustine in the treatment of chronic lymphocytic leukemia
T2 - Results and future perspectives
AU - Aivado, Manuel
AU - Schulte, Karin
AU - Henze, Larissa
AU - Burger, Jan
AU - Finke, Jürgen
AU - Haas, Rainer
N1 - Funding Information:
From the Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine-University, Düsseldorf; and the Department of Hematology and Oncology, University of Freiburg, Freiburg, G ermany. The clinical trial described in this article was supported financially by Ribosepharm G mbH, Munich, G ermany. Address reprint requests to Manuel Aivado, MD, Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, G ermany. Copyright 2002, Elsevier Science (USA). All rights reserved. 0093-7754/02/2904-1305$35.00/0 doi:10.1053/sonc.2002.34875
PY - 2002
Y1 - 2002
N2 - Chronic lymphocytic leukemia (CLL) occurs predominantly in elderly patients. The treatment options for patients with CLL have increased with the introduction of purine analogs, and promising results have been reported with fludarabine and cladribine when these agents are used in newly diagnosed and relapsed disease. Monoclonal antibodies such as alemtuzumab and rituximab are also clinically active in CLL. The use of purine analogs in combination with monoclonal antibodies may provide additional treatment options and this strategy is being studied in patients with relapsed and refractory CLL. Bendamustine is an alkylating agent with properties of a purine analog and is a promising agent in the treatment of CLL. Bendamustine reduces the number of circulating B lymphocytes by over 90% and shows only partial cross-resistance with other alkylating agents, making it an ideal candidate for the treatment of CLL and for use in combination with other alkylating agents. Bendamustine monotherapy can be given to patients whose disease is refractory to standard therapies. The results of a trial using bendamustine as a salvage treatment in patients with relapsed or refractory, heavily pretreated CLL are discussed here. Bendamustine 100 mg/m2 (days 1 and 2) was found to be an effective treatment for older patients with advanced CLL, with 14 of 21 patients responding. Complete hematologic remission was achieved in six of 21 patients and a further eight patients achieved a partial hematologic remission. The main toxicities were hematologic; nonhematologic side effects were mild and uncommon.
AB - Chronic lymphocytic leukemia (CLL) occurs predominantly in elderly patients. The treatment options for patients with CLL have increased with the introduction of purine analogs, and promising results have been reported with fludarabine and cladribine when these agents are used in newly diagnosed and relapsed disease. Monoclonal antibodies such as alemtuzumab and rituximab are also clinically active in CLL. The use of purine analogs in combination with monoclonal antibodies may provide additional treatment options and this strategy is being studied in patients with relapsed and refractory CLL. Bendamustine is an alkylating agent with properties of a purine analog and is a promising agent in the treatment of CLL. Bendamustine reduces the number of circulating B lymphocytes by over 90% and shows only partial cross-resistance with other alkylating agents, making it an ideal candidate for the treatment of CLL and for use in combination with other alkylating agents. Bendamustine monotherapy can be given to patients whose disease is refractory to standard therapies. The results of a trial using bendamustine as a salvage treatment in patients with relapsed or refractory, heavily pretreated CLL are discussed here. Bendamustine 100 mg/m2 (days 1 and 2) was found to be an effective treatment for older patients with advanced CLL, with 14 of 21 patients responding. Complete hematologic remission was achieved in six of 21 patients and a further eight patients achieved a partial hematologic remission. The main toxicities were hematologic; nonhematologic side effects were mild and uncommon.
UR - http://www.scopus.com/inward/record.url?scp=0036337956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036337956&partnerID=8YFLogxK
U2 - 10.1016/s0093-7754(02)90010-2
DO - 10.1016/s0093-7754(02)90010-2
M3 - Review article
C2 - 12170428
AN - SCOPUS:0036337956
SN - 0093-7754
VL - 29
SP - 19
EP - 22
JO - Seminars in oncology
JF - Seminars in oncology
IS - 4 SUPPL. 13
ER -